Want to see HK:2228 full AI Analyst Report?
Top Page
QuantumPharm, Inc.
(2228)
Select Model
Select Model
Rating:52Neutral
Price Target:
HK$8.00
▲(1.78% Upside)
Action:Reiterated
Date:08/21/26
The score is mainly held back by ongoing operating losses and persistent negative operating/free cash flow, despite strong recent revenue and gross profit growth and a notably improved balance sheet. Technically, near-term momentum is mildly positive, but longer-term trend levels remain a headwind, and valuation is less supportive due to a negative P/E and no dividend yield.
Positive Factors
Revenue and Gross Profit Growth
Strong revenue and gross-profit expansion indicates improving commercial scale and potentially better unit economics. Sustained growth could create operating leverage over time, provided the company converts this momentum into durable operating profitability.
Negative Factors
Deep Operating Losses
Persistent operating losses show that the core cost structure remains heavy relative to revenue. Without meaningful cost discipline or further scale benefits, revenue growth may not translate into sustainable profitability or internally funded expansion.
Read all positive and negative factors
Positive Factors
Negative Factors
Revenue and Gross Profit Growth
Strong revenue and gross-profit expansion indicates improving commercial scale and potentially better unit economics. Sustained growth could create operating leverage over time, provided the company converts this momentum into durable operating profitability.
Read all positive factors
QuantumPharm, Inc. (2228) vs. iShares MSCI Hong Kong ETF (EWH)
Market Cap
HK$30.71B
Dividend Yield3.17%
Average Volume (3M)61.94M
Price to Earnings (P/E)―
Beta (1Y)0.83
Revenue Growth3.85%
EPS Growth6.86%
CountryHK
Employees1,254
SectorGeneral
Sector StrengthN/A
IndustryBiotechnology
Share Statistics
EPS (TTM)-0.05
Shares Outstanding4,303,015,000
10 Day Avg. Volume56,697,314
30 Day Avg. Volume61,944,060
Financial Highlights & Ratios
PEG Ratio-2.56
Price to Book (P/B)3.42
Price to Sales (P/S)41.11
P/FCF Ratio-160.72
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
HK$9.20Price Target Upside16.98% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering4
EPS Forecast (FY)-0.03
Revenue Forecast (FY)HK$988.59M
QuantumPharm, Inc. Business Overview & Revenue Model
Company Description
XtalPi Holdings Limited functions as an investment holding company, delivering sophisticated drug discovery and intelligent automation solutions across key markets including China, the United States, Europe, South Korea, and Japan. Its comprehensi...
QuantumPharm, Inc. Financial Statement Overview
Summary
Income Statement
34
Negative
Balance Sheet
58
Neutral
Cash Flow
26
Negative
| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 668.98M | 781.85M | 266.43M | 174.42M | 133.35M | 62.80M |
| Gross Profit | 344.67M | 544.71M | 123.43M | 48.24M | 66.09M | 32.78M |
| EBITDA | -274.74M | 253.59M | -631.38M | -1.78B | -1.38B | -2.11B |
| Net Income | -208.16M | 120.54M | -1.52B | -1.91B | -1.44B | -2.14B |
Balance Sheet | ||||||
| Total Assets | 12.62B | 10.22B | 4.35B | 4.01B | 4.32B | 4.38B |
| Cash, Cash Equivalents and Short-Term Investments | 8.67B | 7.07B | 3.10B | 2.83B | 3.47B | 3.83B |
| Total Debt | 3.12B | 443.46M | 148.76M | 11.04B | 9.45B | 7.83B |
| Total Liabilities | 3.53B | 786.95M | 362.43M | 11.25B | 9.63B | 7.99B |
| Stockholders Equity | 9.00B | 9.39B | 3.96B | -7.27B | -5.33B | -3.61B |
Cash Flow | ||||||
| Free Cash Flow | -359.21M | -199.96M | -536.79M | -698.20M | -627.83M | -417.42M |
| Operating Cash Flow | -279.77M | -139.62M | -478.68M | -567.56M | -429.10M | -253.75M |
| Investing Cash Flow | -4.44B | -3.87B | 74.09M | 735.58M | -2.76B | -70.47M |
| Financing Cash Flow | 5.11B | 5.43B | 840.00M | -25.89M | 57.99M | 2.48B |
QuantumPharm, Inc. Technical Analysis
Negative
7.86
Price Trends
7.49
Negative
7.85
Negative
9.19
Negative
Market Momentum
-0.07
Positive
44.07
Neutral
16.33
Positive
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For HK:2228, the sentiment is Negative. The current price of 7.86 is above the 20-day moving average (MA) of 7.60, above the 50-day MA of 7.49, and below the 200-day MA of 9.19, indicating a bearish trend. The MACD of -0.07 indicates Positive momentum. The RSI at 44.07 is Neutral, neither overbought nor oversold. The STOCH value of 16.33 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for HK:2228.
QuantumPharm, Inc. Peers Comparison
UnderperformOutperform
Sector (55)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
77 Outperform | HK$51.18B | 22.52 | 10.95% | 2.17% | 14.03% | 36.55% | |
57 Neutral | HK$14.25B | 25.15 | 4.62% | 160.60% | 7.92% | 152.75% | |
55 Neutral | $6.65B | 3.83 | -15.92% | 6.20% | 10.91% | 7.18% | |
52 Neutral | HK$30.71B | -118.55 | -2.26% | 3.17% | 3.85% | 6.86% | |
52 Neutral | HK$4.04B | 49.56 | 1.88% | 1.05% | 16.87% | ― | |
49 Neutral | HK$478.64M | -4.59 | -6.22% | ― | -27.63% | -16.33% |
* General Sector Average
HK:2228
QuantumPharm, Inc.
7.14
-3.13
-30.46%
HK:0241
Alibaba Health Information Technology
3.14
-3.56
-53.11%
HK:1833
Ping An Healthcare and Technology Company
6.47
-15.42
-70.45%
HK:2389
Beijing Health (Holdings) Limited
0.08
>-0.01
-8.24%
HK:2158
Yidu Tech, Inc.
3.81
-2.27
-37.38%
HK:2506
Xunfei Healthcare Technology Co., Ltd.
70.90
-34.70
-32.86%
QuantumPharm, Inc. Corporate Events
XtalPi Swings to Loss as R&D Spending Surges in Push into AI for Science
Aug 19, 2026
XtalPi Holdings Limited reported interim unaudited results for the six months ended June 30, 2026, showing revenue of RMB393.6 million, down from RMB517.1 million a year earlier. The group swung to a loss of RMB224.9 million from a prior-period pr...
XtalPi Sets August Board Meeting to Approve Interim Results and Potential Dividend
Aug 7, 2026
XtalPi Holdings Limited has scheduled a board meeting for 19 August 2026 to review and approve the group’s interim financial results for the six months ended 30 June 2026 and to authorize their publication. The board will also consider wheth...
XtalPi Says Redco Disciplinary Action Will Not Affect Its Operations or Director
Jul 30, 2026
XtalPi Holdings disclosed that the Hong Kong Stock Exchange has issued a disciplinary statement against Redco Healthy Living Company Limited and two of its directors over fund flows and transactions between March 2022 and June 2023. The announceme...
XtalPi Flags Interim Loss as R&D Push Weighs on Earnings
Jul 24, 2026
XtalPi Holdings Limited has warned investors that it expects to swing to a net loss of about RMB215 million to RMB275 million for the six months ended June 30, 2026, compared with a net profit of roughly RMB82.8 million a year earlier. The company...
XtalPi Grants New Share Options and RSUs to Executive Team
Jul 2, 2026
XtalPi Holdings Limited has granted 34,980,210 share options and 8,680,822 restricted share units under its 2026 Share Scheme, with the awards subject to acceptance by designated grantees. The move underscores the company’s use of equity-bas...
XtalPi Strikes US$400 Million GPCR Drug Discovery Pact with Global Biopharma Partner
Jun 9, 2026
XtalPi Holdings Limited has entered a strategic partnership with a leading international biopharmaceutical company to develop best-in-class oral small-molecule therapeutics targeting a complex G protein-coupled receptor implicated in metabolic dis...
XtalPi Launches Up to US$100 Million On-Market Share Buyback
Jun 9, 2026
XtalPi Holdings Limited has approved an on-market share repurchase plan of up to US$100 million, allowing the company to buy back as many as 430,337,176 shares, or up to 10% of its issued share capital, on the open market. The buyback window runs ...
XtalPi Wins U.S. Safety Nod for Oral Peptide, Advances Pan-TEAD Cancer Drug
May 31, 2026
XtalPi has advanced its AI-driven peptide business with Tensotide, an innovative oral peptide ingredient developed on its PepiX platform that has secured Self GRAS certification in the U.S. This recognition, following earlier registrations of its ...
XtalPi Advances AI-Driven DoveTree Drug Collaboration, Unlocking Major Milestone Potential
May 27, 2026
XtalPi Holdings Limited reported strong progress in its collaboration with DoveTree, under which it applies its AI-plus-robotics drug discovery platform to multiple disease targets selected by its partner. DoveTree holds exclusive worldwide develo...
XtalPi Co-founders Extend Lock-up on 12.9% Stake to 2027
May 25, 2026
XtalPi Holdings Limited said its three co-founders and executive directors, Dr. Wen Shuhao, Dr. Ma Jian and Dr. Lai Lipeng, have voluntarily extended the lock-up on a large portion of their shareholdings for an additional 12 months. The new expiry...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.